Risk Factors Update Summary

• The Company's charter authorizes 100,000,000 shares of common stock and 20,000,000 shares of Preferred Stock.
• Completed first human trial for PT00114, seeking to prove safety and efficacy, on September 26, 2023.
• The Compensation Committee will review and recommend the frequency of Say on Pay Votes based on stockholder feedback.
• Audit fees increased from $85,000 to $100,000, and audit-related fees increased from $68,000 to $85,000.
• The Company issued 717,000 options with an exercise price of $1.74, vesting between 24-48 months.
• Anticipate Phase I/IIa study initiation for PT00114 in Q2 2024, evaluating safety and tolerability.
• The Company entered a consulting agreement, paying $5,000 per month and issuing 4,400 options.
• Increase in research and development expenses from $1,136,589 in 2022 to $1,449,730,628 in 2023.
• The Committee will oversee management's succession plans for senior positions, including the CEO role.
• The company will need to establish a reserve for foreign earnings as of December 31, 2023.
• Total operating and administrative expenses increased from $3,557,788 to $4,526,974.
• The Audit Committee Charter adoption date changed from March 31, 2023, to April 1, 2024.
• Total comprehensive loss decreased from $3,984,063 to $4,437,136.
• Loss from operations increased from $3,557,788 to $4,526,974.
• Generalized anxiety disorder market expected to reach $1.8 billion by 2023, up from $483 million in 2019.
• Cash decreased from $1,287,893 to $215,189, and marketable securities decreased from $7,763,517 to $2,768,119.
• The Compensation Committee will assess the adequacy of its charter annually and report the results to the Board.
• The requirement to file U... will start from the year ended December 31, 2023.
• Interest income increased from $185,790 to $264,476.
• Opioid use disorder therapies market projected to reach $8.4 billion by 2033, up from $3.5 billion in 2023.
• Director, Timothy Wright, joined in November 2022, filling an open board seat vacated by Joshua Silverman.
• Reverse stock split implemented on March 22, 2023, to maintain listing compliance at $1.00 per share.